KR20200012949A - 과민성 방광의 치료를 위한 비베그론의 용도 - Google Patents

과민성 방광의 치료를 위한 비베그론의 용도 Download PDF

Info

Publication number
KR20200012949A
KR20200012949A KR1020197038625A KR20197038625A KR20200012949A KR 20200012949 A KR20200012949 A KR 20200012949A KR 1020197038625 A KR1020197038625 A KR 1020197038625A KR 20197038625 A KR20197038625 A KR 20197038625A KR 20200012949 A KR20200012949 A KR 20200012949A
Authority
KR
South Korea
Prior art keywords
subject
vibegron
dose
bibegron
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197038625A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 씨. 피씨텔리
폴 머드
Original Assignee
유로반트 사이언시즈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62815097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20200012949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유로반트 사이언시즈 게엠베하 filed Critical 유로반트 사이언시즈 게엠베하
Priority to KR1020257020007A priority Critical patent/KR20250099259A/ko
Publication of KR20200012949A publication Critical patent/KR20200012949A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020197038625A 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도 Ceased KR20200012949A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257020007A KR20250099259A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762515996P 2017-06-06 2017-06-06
US62/515,996 2017-06-06
US201862635146P 2018-02-26 2018-02-26
US62/635,146 2018-02-26
US201862637961P 2018-03-02 2018-03-02
US62/637,961 2018-03-02
PCT/IB2018/054069 WO2018224989A1 (en) 2017-06-06 2018-06-06 Use of vibegron to treat overactive bladder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257020007A Division KR20250099259A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도

Publications (1)

Publication Number Publication Date
KR20200012949A true KR20200012949A (ko) 2020-02-05

Family

ID=62815097

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197038625A Ceased KR20200012949A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도
KR1020257020007A Pending KR20250099259A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257020007A Pending KR20250099259A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도

Country Status (14)

Country Link
US (2) US12102638B2 (https=)
EP (2) EP3634420A1 (https=)
JP (3) JP7682605B2 (https=)
KR (2) KR20200012949A (https=)
CN (3) CN117695286A (https=)
AU (2) AU2018282104B2 (https=)
BR (1) BR112019025636A2 (https=)
CA (1) CA3064989A1 (https=)
CL (1) CL2019003533A1 (https=)
IL (2) IL317220A (https=)
MX (1) MX2022015629A (https=)
PH (1) PH12019502651A1 (https=)
WO (1) WO2018224989A1 (https=)
ZA (1) ZA202000028B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102020124101A1 (de) 2020-02-04 2021-08-05 Samsung Electronics Co., Ltd. Elektronische vorrichtung mit einer speichervorrichtung und trainingsverfahren

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102735800B1 (ko) * 2017-12-21 2024-11-28 교린 세이야쿠 가부시키가이샤 야간빈뇨 치료제
SG11202103662VA (en) * 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
JP2022524576A (ja) * 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
CA3202926A1 (en) * 2020-12-22 2022-06-30 Paul N. Mudd Jr. Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder
WO2025262600A1 (en) 2024-06-17 2025-12-26 Urovant Sciences Gmbh Crystalline form of vibegron hemihydrate

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE266639T1 (de) 1997-10-17 2004-05-15 Yamanouchi Pharma Co Ltd Amidderivate oder deren salze
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
DK1559427T3 (da) 2002-11-07 2011-04-26 Astellas Pharma Inc Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel
DK1620085T3 (da) 2003-05-05 2008-11-24 Kissei Pharmaceutical Anvendelse af phenoxyacetatsyrederivater til behandling af hyperaktiv blære
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
CA2682676A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
EP2198018B1 (en) 2007-09-13 2013-11-20 Codexis, Inc. Ketoreductase polypeptides for the reduction of acetophenones
CA2704298C (en) 2007-11-02 2015-07-21 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
US8273554B2 (en) 2008-08-29 2012-09-25 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
WO2011043942A1 (en) 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
AU2011285928B9 (en) 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
AU2012323890A1 (en) 2011-10-14 2014-05-29 Array Biopharma Inc. Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
IN2014CN04470A (https=) 2011-11-18 2015-09-04 Codexis Inc
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
RS59402B1 (sr) 2013-03-15 2019-11-29 Merck Sharp & Dohme Postupak za pripremu beta 3 agonista i međuproizvoda
HK1245117A1 (zh) 2014-12-03 2018-08-24 Velicept Therapeutics, Inc. 使用调节释放索拉贝隆用於下尿路症状的组合物和方法
ES2967863T3 (es) 2015-10-23 2024-05-06 B3Ar Therapeutics Inc Ion dipolar de solabegron y usos del mismo
US20170348288A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
EP3463307A4 (en) 2016-06-03 2020-01-15 Velicept Therapeutics, Inc. COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS
JP7670461B2 (ja) 2017-06-06 2025-04-30 ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング 過活動膀胱の治療のためのビベグロンの投薬
KR102735800B1 (ko) 2017-12-21 2024-11-28 교린 세이야쿠 가부시키가이샤 야간빈뇨 치료제
SG11202010683PA (en) 2018-05-23 2020-12-30 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
SG11202103662VA (en) 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
JP2022524576A (ja) 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
CA3202926A1 (en) 2020-12-22 2022-06-30 Paul N. Mudd Jr. Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder
TW202245781A (zh) 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102020124101A1 (de) 2020-02-04 2021-08-05 Samsung Electronics Co., Ltd. Elektronische vorrichtung mit einer speichervorrichtung und trainingsverfahren

Also Published As

Publication number Publication date
US20210077495A1 (en) 2021-03-18
IL271164A (en) 2020-01-30
CN110869022A (zh) 2020-03-06
MX2022015629A (es) 2023-01-11
US20260014158A1 (en) 2026-01-15
JP2025063196A (ja) 2025-04-15
JP2020522560A (ja) 2020-07-30
ZA202000028B (en) 2025-09-25
WO2018224989A1 (en) 2018-12-13
JP2023071826A (ja) 2023-05-23
CL2019003533A1 (es) 2020-06-26
AU2018282104B2 (en) 2024-07-11
JP7682605B2 (ja) 2025-05-26
KR20250099259A (ko) 2025-07-01
EP4410295A3 (en) 2024-10-16
AU2024204591A1 (en) 2024-07-18
IL317220A (en) 2025-01-01
US12102638B2 (en) 2024-10-01
EP4410295A2 (en) 2024-08-07
CA3064989A1 (en) 2018-12-13
AU2018282104A1 (en) 2019-12-12
CN117695287A (zh) 2024-03-15
PH12019502651A1 (en) 2020-06-08
CN117695286A (zh) 2024-03-15
BR112019025636A2 (pt) 2020-08-25
EP3634420A1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
US20260014158A1 (en) Use of vibegron to treat overactive bladder
JP7670461B2 (ja) 過活動膀胱の治療のためのビベグロンの投薬
US20150157575A1 (en) Pharmaceutical Formulations Comprising Vilazodone
EP4545072A2 (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
US20210196720A1 (en) Use of vibegron to treat pain associated with irritable bowel syndrome
JP6682533B2 (ja) 多汗症を治療するための方法
HK40114255A (en) Use of vibegron to treat overactive bladder
EA045454B1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
TW202444359A (zh) 用於向患有肝損傷的患者施用帕妥索汀的組合物和方法
HK40084818B (zh) 治疗慢性肾病的方法和药物组合物
HK40126413A (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
EA052961B1 (ru) Вибегрон для лечения симптомов гиперактивного мочевого пузыря
Capsules COMPANY CORE DATA SHEET RITONAVIR Ritonavir tablets Ritonavir oral powder Ritonavir oral solution

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201